ClinicalTrials.gg
WithdrawnNCT06765902Updated May 5, 2026

Immunotherapy Before and After Surgery

A Phase 2 interventional study of N-803 and ETBX-071 in High-risk Prostate Cancer, sponsored by ImmunityBio, Inc.. Withdrawn. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-05.

Sponsored by ImmunityBio, Inc. · Phase 2, Interventional, and Treatment

Why this study was withdrawn
Study was redeveloped into a new protocol

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
18 Years and older
Sex
Male
01

Study summary

This Phase 2 clinical trial is testing a new immunotherapy combination (N-803, ETBX-071, M-CENK) for men with high-risk prostate cancer before and after prostate surgery. The goal is to see if this treatment improves cancer outcomes and is safe.

Read the detailed description

This study is an open-label, Phase 2 clinical trial investigating the efficacy and safety of a three-part immunotherapy regimen in combination with surgery for men with high-risk prostate cancer who have not yet undergone a prostatectomy. The immunotherapy consists of three components:

N-803 (Nogapendekin Alfa Inbakicept): A soluble complex consisting of a modified human interleukin-15 (IL-15) variant bound to a human IL-15 receptor alpha subunit/human immunoglobulin G (IgG) Fc fusion protein. N-803 acts as a growth and activation factor for natural killer (NK) cells and effector and memory T-cells, enhancing their ability to kill cancer cells and stimulate an immune response. It is administered subcutaneously.

ETBX-071 (hAd5 [E1-, E2b-, E3-]-PSA Vaccine): A replication-defective human adenovirus serotype 5 vector modified to encode human prostate-specific antigen (PSA). This vaccine is designed to induce a cell-mediated immune response against PSA-expressing prostate cancer cells. It is administered subcutaneously.

M-CENK (Autologous Memory Cytokine-Enriched NK Cells): These are the patient's own NK cells that are collected through apheresis, expanded and activated ex vivo using cytokines (IL-12, IL-15, and IL-18) to enhance their cytotoxicity and IFN-γ production. The resulting M-CENK cells are then infused intravenously.

Study Design:

The study involves three main phases:

Pre-surgery Immunotherapy: Participants receive N-803, ETBX-071, and M-CENK according to a specific schedule for six weeks before undergoing prostatectomy.

Surgery: Participants undergo a radical prostatectomy.

Post-surgery Immunotherapy: Following surgery, participants receive four cycles of the same immunotherapy regimen (N-803, ETBX-071, and M-CENK) over a 24-week period. Some participants may also receive external beam radiation therapy (EBRT) post-surgery at the discretion of the investigator.

Endpoints:

The study will assess several endpoints, including:

Primary Endpoints: Event-free survival (EFS) and biochemical recurrence-free survival (bRFS) are the main measures of the treatment's effectiveness in preventing cancer recurrence.

Secondary Endpoints: These include the rate of PSA reduction within six months post-surgery and safety assessments (adverse events, serious adverse events, changes in vital signs and laboratory tests).

Exploratory Endpoints: These are additional measures to assess quality of life, sexual function, immune responses, and changes in the tumor microenvironment.

Patient Selection:

The study includes men with high-risk prostate cancer, defined by specific criteria related to PSA levels, Gleason score, and tumor stage. Participants must meet specific inclusion criteria and cannot have certain pre-existing conditions or prior treatments that might interfere with the study.

Follow-up:

Participants will be followed for up to five years after completing the treatment, with regular monitoring and assessments.

This detailed description provides a more comprehensive overview of the study's design, methodology, and objectives.

02

Conditions studied

  • High-risk Prostate Cancer

Browse trials for

Keywords

  • Prostate Cancer
  • High-risk prostate cancer
  • Immunotherapy
  • N-803
  • ETBX-071
  • M-CENK
  • Radical prostatectomy
  • Pre-surgery immunotherapy
  • Post-surgery immunotherapy
03

In context

Prostatic Neoplasms

7,052 studies on the registry are indexed under Prostatic Neoplasms; 1,583 are open to participants now.

Browse Prostatic Neoplasms studies →

Lead sponsor

ImmunityBio, Inc. is the lead sponsor of 83 studies on the registry; 14 are open to participants now.

Of its 23 completed or terminated interventional studies of FDA-regulated products, 17 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age: Must be 18 years or older.
  • Consent: Able to understand and provide signed that complies with Institutional Review Board (IRB) or Independent Ethics Committee (IEC) guidelines.
  • Diagnosis: confirmed prostate adenocarcinoma (unless a local pathologist's report shows consistent findings).
  • Performance Status: (ECOG) performance status of 0 or 1.
  • : Must have a life expectancy of at least 10 years.
  • Germline Testing: Must have undergone germline testing at the time of initial diagnosis (and at recurrence, if applicable).
  • : No evidence of soft tissue disease metastasis (visceral or lymph nodes) on CT/MRI scan.
  • Disease: No active or organ-threatening autoimmune disease.
  • High-Risk Prostate Cancer: Must have high-risk or very high-risk prostate cancer according to 2024 NCCN guidelines (PSA >20 ng/mL, or Gleason Grade Group ≥4, or ≥cT3a).
  • Adequate Hematologic and Organ Function: Must meet specific criteria for (ANC), lymphocyte count, count, , or aPTT, , ALT, and alkaline phosphatase levels. Certain exceptions are made for participants with liver or bone metastases.
  • Ability to Attend Visits: Must be able to attend required study visits and return for adequate follow-up.
  • : If male and not surgically sterile, must agree to use effective contraception for up to 7 months after treatment.

Exclusion criteria

Exclusion Criteria:

  • Prior Prostate Treatments: Prior surgical, cryotherapy, or high-intensity focused ultrasound treatment for prostate cancer; prior orchiectomy or hormonal therapy (GnRH agonists, NSAA).
  • Prior Anti-Androgen Therapy: Prior treatment with first-generation or second-generation androgen receptor (AR) inhibitors (e.g., bicalutamide, flutamide, nilutamide, cyproterone acetate; enzalutamide, apalutamide, or darolutamide).
  • Organ Transplantation: Receipt of any organ transplantation (excluding those that don't require , like corneal or hair transplants).
  • Use: Chronic systemic corticosteroid administration (>14 days within 28 days before treatment initiation) except for topical, inhaled, or nasal corticosteroids.
  • Active Disease: Active autoimmune disease (e.g., Addison's disease, Hashimoto's thyroiditis, systemic lupus erythematosus, Sjogren's syndrome, scleroderma, myasthenia gravis, Goodpasture syndrome, or active Graves' disease). Exceptions are made for those with a history of autoimmune disease that did not require systemic immunosuppression and does not threaten vital organ function.
  • Medications Affecting Urinary Symptoms or PSA: Use of medications for urinary symptoms (5-alpha reductase inhibitors, alternative medications known to alter PSA levels) within 28 days prior to study initiation.
  • Recent Major Surgery or Systemic Therapy: Major surgery or systemic therapy (including therapies) within 28 days prior to study initiation.
  • Allergic Reactions: History of allergic reactions to compounds with similar chemical or biological composition to the study drugs.
  • Significant Cardiovascular or Cerebrovascular Disease: cardiovascular/cerebrovascular disease (e.g., stroke, myocardial infarction, unstable angina, congestive heart failure, serious cardiac arrhythmia, or uncontrolled hypertension) within six months prior to the first planned dose of study drugs.
  • Intercurrent Medical Illness: Serious intercurrent medical illness that would interfere with participation.
  • Infections: Active , or C infection.
  • : Administration of a live, attenuated vaccine within three weeks before study entry or anticipation that such a vaccine will be required during the study.
  • Inability to Comply: The investigator deems the participant unable or unwilling to comply with study requirements.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Standard of Care + Immunotherapy in addition to surgery.

    The experimental arm of this study is the treatment group receiving the combination of pre- and post-surgery immunotherapy with N-803, ETBX-071, and M-CENK in addition to surgery.

    Drug: N-803 · Drug: ETBX-071 · Drug: M-CENK

Interventions

  • DrugN-803

    A subcutaneous injection of an IL-15 superagonist.

  • DrugETBX-071

    A subcutaneous injection of a prostate-specific antigen (PSA) adenovirus vaccine.

  • DrugM-CENK

    An intravenous infusion of the patient's own NK cells that have been expanded and activated in a laboratory.

06

What researchers measure

Primary outcomes

  1. Event-free survival (EFS)

    The length of time from surgery to the first occurrence of disease recurrence (biochemical failure, local/regional recurrence, distant metastasis) or death.

    Time frame: These are assessed from the date of surgery until the occurrence of disease recurrence (EFS) or biochemical recurrence (bRFS), or until the end of the five-year follow-up period.

  2. Biochemical recurrence-free survival (bRFS)

    The length of time from surgery to the first evidence of biochemical recurrence (two sequential increases in PSA levels by \>0.2 ng/ml within 3-4 weeks) or death.

    Time frame: These are assessed from the date of surgery until the occurrence of disease recurrence (EFS) or biochemical recurrence (bRFS), or until the end of the five-year follow-up period.

Secondary outcomes

  1. Rate of PSA reduction

    The percentage decrease in PSA levels within six months post-surgery.

    Time frame: Assessed within 6 months post-surgery.

  2. Safety (AEs and SAEs)

    Assessment of adverse events (AEs), serious adverse events (SAEs), and clinically important changes in laboratory values and vital signs.

    Time frame: Up to 260 weeks.

Other outcomes

  1. Quality of life (QoL):

    Assessed using validated questionnaires (EPIC-26 and PROMIS).

    Time frame: Approximately 13 months

  2. Sexual function

    Assessed using the Sexual Health Inventory for Men (SHIM)

    Time frame: Approximately 13 months

  3. Changes in immune subsets and antigen-specific immune responses

    Measured at baseline and end of treatment.

    Time frame: Approximately 13 months

  4. Tumor microenvironment (TME) changes

    The tumor microenvironment (TME) is the complex ecosystem of cells, molecules, and extracellular matrix that surrounds and interacts with tumor cells.

    Time frame: Approximately 13 months

  5. Circulating tumor DNA (ctDNA)

    Levels measured to monitor minimal residual disease.

    Time frame: Approximately 13 months

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2025; primary completion for Jan 2031, 61 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 23, 2024
First posted
Jan 9, 2025
StartEst.
Dec 15, 2025
Primary completionEst.
Jan 31, 2031
CompletionEst.
Jun 30, 2031
Last update
May 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06765902
Lead sponsor
ImmunityBio, Inc.
Responsible party
Sponsor
First posted
Jan 9, 2025
Start date
Dec 15, 2025 (estimated)
Primary completion
Jan 31, 2031 (estimated)
Completion
Jun 30, 2031 (estimated)
Last update
May 5, 2026

Study contacts

Bruce Brown
study chair · ImmunityBio, Inc.

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion